文献速递肿瘤 PET/CT

F-18 FDG PET/CT在非结膜起源眼附属器MALT淋巴瘤中的作用

Role of F-18 FDG PET/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas.
PubMed 文献 · EJNMMI Res · 2019-11-21

回顾性分析50例非结膜起源眼附属器MALT淋巴瘤患者,评估FDG PET/CT分期价值并与MRI比较。83.3%病灶FDG摄取,PET/CT与MRI灵敏度相当,14%患者因检出眼外病灶而分期上调。

要点

  • 非结膜起源OAML中83.3%为FDG高摄取肿瘤,平均SUVmax 4.8±2.4。
  • FDG PET/CT与MRI检测原发肿瘤灵敏度分别为83.1%和89.8%,无统计学差异。
  • 14%患者经PET/CT检出未预料眼外病灶,指导治疗管理。

核心结论

  • 非结膜起源OAML中83.3%为FDG高摄取肿瘤,FDG PET/CT灵敏度与MRI相当。
  • FDG PET/CT检出14%患者未预料眼外淋巴瘤受累,可能指导治疗管理。

研究设计与样本

  • 回顾性分析2009年1月至2016年2月123例病理证实的OAML患者,排除结膜起源后纳入50例非结膜起源OAML。
  • 分析60个OAML病灶(10例双侧),测量SUVmax等PET参数,并与MRI灵敏度比较。

主要发现

  • 50个病灶(83.3%)为FDG高摄取,平均SUVmax 4.8±2.4(范围2.0~11.1)。
  • 按部位平均SUVmax:眼睑3.7±1.1,泪腺3.6±1.4,眼眶5.7±2.6,三部位间差异有统计学意义(P=0.010)。
  • FDG PET/CT灵敏度83.1%(49/59),MRI灵敏度89.8%(53/59),McNemar检验P=0.219。
  • 7例(14%)患者经FDG PET/CT检出眼外病灶而分期上调(肾和肺1例、扁桃体1例、颈部淋巴结4例、骶孔1例)。

关键数值与推荐

  • FDG高摄取肿瘤定义为FDG-avid,50/60病灶(83.3%)符合。
  • 原发肿瘤检测灵敏度:FDG PET/CT 83.1%(49/59),MRI 89.8%(53/59)。
  • 分期上调率14%(7/50)基于FDG PET/CT检出眼外病灶。

临床怎么用

  • FDG PET/CT可用于非结膜起源OAML分期,灵敏度与MRI相当。
  • PET/CT可检出未预料眼外病灶,影响14%患者分期,可能指导治疗决策。

局限性

  • 回顾性研究设计。
  • 1例患者MRI缺失,灵敏度分析基于59个病灶。
  • 样本量50例,非结膜起源OAML相对少见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the widespread use of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in the diagnosis and response assessment of patients with lymphoma, few studies have assessed its value in ocular adnexal lymphomas. The purpose of this study was to evaluate the role of FDG PET/CT in staging of non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas (OAML). In addition, the diagnostic sensitivity of FDG PET/CT was compared with magnetic resonance imaging (MRI). FDG PET/CT of 123 consecutive patients with pathologically proven OAML between January 2009 and February 2016 were retrospectively reviewed. The patients with MALT lymphoma originating from conjunctiva were excluded. A total 50 patients with non-conjunctival origin OAML were assessed. Maximum standardized uptake value (SUVmax) and additional PET parameters were measured for all lesions. Sensitivity for primary tumor detection was compared with MRI. RESULTS: Ten patients had bilateral OAML and total 60 OAML lesions were analyzed. MRI was missing in one patient. The tumor locations were as follows: eyelid, 9; lacrimal gland, 18; orbit, 33. Fifty lesions (83.3%) were FDG-avid tumors with mean ± SD SUVmax 4.8 ± 2.4 (range 2.0~11.1). The mean SUVmax according to tumor location were as follows: eyelid, 3.7 ± 1.1 (2.8~5.3); lacrimal gland, 3.6 ± 1.4 (2.1~6.4); orbit, 5.7 ± 2.6 (2.0~11.1). Mean SUVmax among the 3 locations were statistically different (P = 0.010). The sensitivity was calculated as 83.1% (49/59) for FDG PET/CT and 89.8% (53/59) for MRI, which were statistically comparable (P = 0.219 by McNemar's test). Seven of 50 patients (14%) were upstaged by detection of extraocular lesions by FDG PET/CT (1 kidney and lung, 1 tonsil, 4 cervical LNs, 1 sacral foramen). CONCLUSION: 83.3% of the non-conjunctival origin OAML were FDG-avid tumors, with FDG PET/CT showing comparable sensitivity to that of MRI. FDG PET/CT detected unsuspected extraocular lymphoma involvement in 14% of the patients. FDG PET/CT performed for staging of non-conjunctival origin OAML may thus guide therapeutic management.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Park HL, O JH, Park SY, et al. Role of F-18 FDG PET/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas. EJNMMI Res. 2019. PMID: 31754896. doi:10.1186/s13550-019-0562-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。